Pharmacology News

Among older patients on a direct oral anticoagulant, those who took clarithromycin had a small, statistically significant increased risk for major hemorrhage at 30 days vs. those taking azithromycin, researchers found.

Physicians across five countries in Europe reported decreasing satisfaction with treatment for their patients with osteoarthritis, as well as increasing disease severity despite the rising use of opioids, according to findings presented at EULAR 2020.

A novel predictive model appeared to identify patients who may progress into persistent high-dose opioid use and dependence following total knee replacement, according to data presented at the EULAR 2020 E-Congress.

Patients with moderate COVID-19 who received remdesivir for 5 days were 65% more likely to show clinical improvement compared with those who received usual care, according to results from a phase 3 clinical trial released by the manufacturer.

Researchers from the University of Kentucky are conducting a clinical trial to evaluate the effectiveness of azithromycin, ivermectin and camostat mesylate alone or combined with hydroxychloroquine in high-risk patients with COVID-19.

Dana-Farber Cancer Institute announced the launch of a randomized clinical trial evaluating the use of ibrutinib — an oral medication used to treat blood cancer — in patients with COVID-19.

Global adoption of a European Union regulation may improve the public image of and sentiment toward the pharmaceutical industry, according to research presented at the American Society of Clinical Psychopharmacology Annual Meeting.

The FDA recently approved an oral estrogen and progestin combination capsule for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, according to an agency press release.

Patients with kidney failure who were dispensed a short-acting benzodiazepine in combination with opioids had an increased risk for mortality within 1 year of initiating hemodialysis, according to study results.

Just 16.6% of commercially insured patients receive follow-up care after being released from the ED for a nonfatal opioid overdose, according to a study published in JAMA Network Open.